Company Will Host Webcast to Review Data Tuesday, May 13 at 1:00 p.m. EDT

(7:00 p.m. CEST)

BARCELONA, Spain and MENLO PARK, Calif., May 13 /PRNewswire-FirstCall/
-- XTENT, Inc. (Nasdaq: XTNT) today announced positive six-month follow-up
data from the CUSTOM III clinical trial, which assessed the safety and
efficacy of the Custom NX(R) drug eluting stent (DES) system for the
treatment of patients with coronary artery disease.

The CUSTOM III clinical trial was a 90-patient prospective study to
assess the safety and efficacy of the Custom NX drug eluting stent system
in patients with up to two de novo lesions treatable with up to 60 mm of
customizable stent length. The primary endpoint was major adverse cardiac
events (MACE) at 30 days, with secondary endpoints of MACE at six months,
binary restenosis, late loss, and stent thrombosis.

CUSTOM III enrolled a challenging patient population, with 67 percent
of the lesions classified as complex B2/C, an average lesion length of 19.8
mm, and an average reference vessel diameter (RVD) of 2.6 mm. The CUSTOM
III trial included some of the longest lesion lengths and smallest RVDs
compared to previous drug eluting stent trials. Lesion length and RVD are
two important indicators of disease complexity.

For the primary endpoint, MACE at 30 days, the rate was 2.2 percent,
consisting of two in-hospital non Q-wave myocardial infarctions (MIs). At
six-month follow-up the MACE rate for CUSTOM III was 7.8 percent. There
were zero deaths, zero Q-wave MIs, two non Q-wave MIs, or 2.2 percent, and
five clinically driven target lesion revascularizations, or 5.6 percent.
There was one case of early stent thrombosis in the trial and zero late
stent thrombosis. The in-stent late loss for CUSTOM III at six-month
follow-up was 0.17 mm, the in-stent binary restenosis rate was 4.4 percent,
and the neointimal hyperplasia (NIH) volume was 3.8 percent.

"The CUSTOM III results are very promising and demonstrate the safety
of in situ customization for treatment of simple and complex lesions. The
IVUS and angiographic results confirm the efficacy of the Custom NX stent,
and the Biolimus A9(R) and PLA formulation," said Bernard De Bruyne, M.D.,
Ph.D., of the OLV Clinic in Aalst, Belgium, and Principal Investigator for
the CUSTOM III clinical trial.

"Given the complexity of the patient population from CUSTOM III, we are
excited about the results, which are consistent with the outcomes observed
from the CUSTOM I and CUSTOM II trials," said Gregory D. Casciaro, XTENT's
President and CEO. "We continue to be pleased with the safety profile and
efficacy data of Custom NX in today's real-world patients."

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the
treatment of arterial disease based on each patient's individual lesion
characteristics. The Custom NX system allows physicians to customize the
length and diameter of the stent at the site of the lesion. The system
features a proprietary modular stent design that consists of multiple 6 mm
cobalt chromium segments coated with Biolimus A9(R) and PLA, a
biodegradable drug carrier. The Custom NX delivery system enables
separation at each 6 mm segment and allows for the placement of up to 60 mm
of stent. The Custom NX DES System has not been approved for sale by any
regulatory authority.

CUSTOM III Webcast and Slide Presentation

As previously announced, XTENT will host a teleconference and slide
presentation to review the CUSTOM III data today at 1:00 p.m. EDT (7:00
p.m. CEST). To participate in the conference call, please dial 877-591-4957
(from the U.S.) or 719-325-4895 (international). The webcast and slide
presentation can be accessed via the investor relations section of the
Company's website at http://investor.xtentinc.com/events.cfm. Please dial
in or access the website five to 10 minutes prior to the beginning of the
call. If you do dial in, please also view the slides via the webcast. The
webcast will be archived on the website for a minimum of three months, and
can be accessed at the investor relations portion of the company's website
at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and
commercializing innovative customizable drug eluting stent (DES) systems
for the treatment of coronary artery disease (CAD). CAD is the most common
form of cardiovascular disease and the number one cause of death in the
United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to
enable the treatment of single lesions, long lesions and multiple lesions
of varying lengths and diameters, in one or more arteries with a single
device.

Forward Looking Statements

This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Statements in this press release regarding XTENT's business that are not
historical facts may be "forward-looking statements" that involve risks and
uncertainties. Specifically, these statements include, but are not limited
to those concerning: XTENT's expectations with respect to the timing of the
release of its clinical trial data. Forward-looking statements are based on
management's current, preliminary expectations, and are subject to risks
and uncertainties that could cause actual results to differ from the
results predicted and which are included in the "Risk Factors" section of
XTENT's annual report on Form 10-K for the year ended December 31, 2007.
This annual report was filed with the SEC on March 17, 2008, and is
available on the company's investor relations website at
http://www.xtentinc.com and on the SEC's website at http://www.sec.gov.
Undue reliance should not be placed on forward-looking statements, which
speak only as of the date they are made. XTENT undertakes no obligation to
update publicly any forward-looking statements to reflect new information,
events or circumstances after the date they were made, or to reflect the
occurrence of unanticipated events.

(Date:10/2/2017)... , Oct. 2, 2017 AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...

(Date:9/27/2017)... , Sept. 27, 2017 Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...

(Date:9/22/2017)... As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place. The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...

(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...

(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...

(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...

(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...

(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...